Cabozantinib 60 mg Tablets UK
is a once-daily oral targeted therapy for advanced kidney, liver, and medullary thyroid cancers. It works by blocking cancer cell growth and angiogenesis via inhibition of multiple tyrosine kinase receptors. This 60 mg strength is the standard starting dose for most adult patients. Must be taken under the supervision of a healthcare provider.
Cabozantinib Tablets 60 mg is an oral targeted therapy used in the treatment of advanced kidney cancer (renal cell carcinoma – RCC), liver cancer (hepatocellular carcinoma – HCC), and medullary thyroid cancer (MTC). It belongs to a class of medications called tyrosine kinase inhibitors (TKIs) and works by blocking multiple cancer-driving proteins involved in tumor growth, metastasis, and angiogenesis (formation of new blood vessels).
This 60 mg strength is the standard recommended daily dose for adult patients with advanced-stage cancers, administered once daily on an empty stomach.
